Drug Trial Radar · NCT04140500
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
170
Actual
Start
Nov 11, 2019
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with advanced and/or metastatic solid tumors. This study aims to establish the maximum tolerated dose (MTD) and/or define the recommended phase 2 dose (RP2D) based on the safety, tolerability, pharmacokinetic (PK) and/or pharmacodynamic (PD) profile of RO7247669, and to evaluate preliminary anti-tumor activity in participants with solid tumors. An expansion part of the study is planned to enroll tumor-specific cohorts to evaluate anti-tumor activity of the MTD and/or RP2D of RO7247669 and to confirm safety and tolerability in participants with selected tumor types.
Conditions
- Solid Tumors
- Metastatic Melanoma
- Non-small Cell Lung Cancer
- Esophageal Squamous Cell Carcinoma
Interventions
RO7247669Drug
Participants will receive intravenous (IV) RO7247669 at different doses either every 2 weeks (Q2W) or every 3 weeks (Q3W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Days 1-21 (Q2W dosing) or Days 1-28 (Q3W dosing) of Cycle 1
- Part A: Percentage of Participants with Adverse EventsTime frame: Baseline through the end of study (up to 24 months)
- Part B: Objective Response Rate (ORR)Time frame: Up to 24 months
- Part B: Disease Control Rate (DCR), Defined as ORR + Stable Disease Rate (SDR)Time frame: Up to 24 months
- Part B: Duration of Response (DOR)Time frame: Up to 24 months
- Part B: Progression-free Survival (PFS), Defined as the Time from the First Study Treatment to the First Occurrence of Progression per Investigator Assessment or Death from any Cause, Whichever Occurs FirstTime frame: Up to 24 months
Locations
25 sites in 9 countries. Site status is shown where the registry gives one.
Rigshospitalet
København Ø, Denmark
Odense Universitetshospital, Onkologisk Afdeling R
Odense C, Denmark
LLC Arensia Explorer Medicine
Tbilisi, Georgia
Hadassah University Hospital - Ein Kerem
Jerusaelm, Israel
Rabin MC
Petah Tikva, Israel
Chaim Sheba medical center, Oncology division
Ramat Gan, Israel
Hospital Civil de Guadalajara Fray Antonio Alcalde
Guadalajara, Jalisco, Mexico
Inst. Nacional de Cancerología
Mexico City, Mexico CITY (federal District), Mexico
Consultorio Médico Jordi Guzmán Casta
Querétaro City, Querétaro, Mexico
National University Hospital
Singapore, Singapore
National Cancer Centre
Singapore, Singapore
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, Spain
Clinica Universidad de Navarra Madrid
Madrid, Spain
START Madrid-FJD, Hospital Fundacion Jimenez Diaz
Madrid, Spain
START Madrid. Centro Integral Oncologico Clara Campal
Madrid, Spain
Clinica Universitaria de Navarra
Pamplona, Navarre, Spain
Adana City Hospital, Medical Oncology
Adana, Turkey (Türkiye)
Ankara City Hospital
Ankara, Turkey (Türkiye)
Hacettepe Uni Medical Faculty Hospital
Sihhiye/Ankara, Turkey (Türkiye)
Ankara Abdurrahman Yurtaslan Oncology Training and Research Hospital Phase 1 Center
Yen?mahalle, Turkey (Türkiye)
Queen Elizabeth Hospital
Birmingham, United Kingdom
Christie Hospital NHS Trust
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.